Speaker(s): 

Ashton Dainty, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Joal Jacob, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Sydney Naylor, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Differentiate the risks and benefits between sublingual and extended-release injectable buprenorphine
• Recognize the effectiveness of treatment engagement between dosage forms
• Describe how procalcitonin and C-reactive protein can guide antibiotic discontinuation in critically ill patients with suspected sepsis
• Evaluate the efficacy of procalcitonin and C-reactive protein-guided therapy vs standard-care methods for antibiotic discontinuation
• Compare 7-day vs 14-day antibiotic durations in bloodstream infections
• Discuss the significance of bloodstream infections and the potential benefits of shorter antibiotic durations

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.